ArticleExpert opinion on investigational drugs2015
Investigational cancer drugs targeting cell metabolism in clinical development.
Article in Expert opinion on investigational drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 72 citations in OpenAlex.
- Research progress and therapeutic strategies in hepatocellular carcinoma metabolic reprogramming.Journal of advanced research · 2026Review
- Glucose oxidase-powered nanocatalytic medicine: Rewiring tumor metabolism for multimodal cancer therapy.Materials today. Bio · 2026Review
- Long noncoding RNAs: glycolysis regulators in gynaecologic cancers.Cancer cell international · 2023Review
- Controlled masking and targeted release of redox-cycling ortho-quinones via a C-C bond-cleaving 1,6-elimination.Nature chemistry · 2022Article
- RIP140 inhibits glycolysis-dependent proliferation of breast cancer cells by regulating GLUT3 expression through transcriptional crosstalk between hypoxia induced factor and p53.Cellular and molecular life sciences : CMLS · 2022Article
- LncRNA-MALAT1 Regulates Cancer Glucose Metabolism in Prostate Cancer via MYBL2/mTOR Axis.Oxidative medicine and cellular longevity · 2022Article
- Review
- Sensing soluble uric acid by Naip1-Nlrp3 platform.Cell death & disease · 2021Article
- Glucose Metabolism in Cancer: The Warburg Effect and Beyond.Advances in experimental medicine and biology · 2021Article
- Metabolic and Immunological Subtypes of Esophageal Cancer Reveal Potential Therapeutic Opportunities.Frontiers in cell and developmental biology · 2021Article
- The ALDOA Metabolism Pathway as a Potential Target for Regulation of Prostate Cancer Proliferation.OncoTargets and therapy · 2021Article
- Fundamentals of T Cell Metabolism and Strategies to Enhance Cancer Immunotherapy.Frontiers in immunology · 2021Review
- Review
- Article
- Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer.Biochimica et biophysica acta. Reviews on cancer · 2020Review
- Biochemical and structural insights into how amino acids regulate pyruvate kinase muscle isoform 2.The Journal of biological chemistry · 2020Article
- ROS in cancer therapy: the bright side of the moon.Experimental & molecular medicine · 2020Review
- Reversal of the Warburg phenomenon in chemoprevention of prostate cancer by sulforaphane.Carcinogenesis · 2019Article
- The pathobiology of polycystic kidney disease from a metabolic viewpoint.Nature reviews. Nephrology · 2019Review
- 2-Deoxy-d-Glucose-Induced Metabolic Alteration in Human Oral Squamous SCC15 Cells: Involvement of N-Glycosylation of Axl and Met.Metabolites · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Introduction: Malignant cell transformation and tumor progression are associated with alterations in glycolysis, fatty acid synthesis, amino acid delivery and production of reactive oxygen species. With increased understanding of the role of metabolism in tumors, there has been interest in developing agents that target tumor specific metabolic pathways. Numerous promising agents targeting altered metabolic pathways are currently in Phase I - III clinical trials. Areas covered: This paper reviews the early phase clinical trial development of these agents and provides perspective on the future direction of this emerging field. Specifically, the authors describe novel and repurposed therapies, focusing on the effects of each agent on tumor metabolism and results from relevant Phase I and II clinical trials. Expert opinion: Metabolism modulating agents, alone and in combinations with other classes of agents, have shown efficacy in the treatment of neoplasm, which, the authors believe, will bear positive results in future studies. Because of the significant crosstalk between metabolic pathways and oncogenic signaling pathways, the authors also believe that combining metabolic modifiers with targeted agents will be an important strategy. An increased understanding of cancer metabolism, in addition to the continued study of metabolic modulators, should lead to further advances in this nascent therapeutic field in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.